A placebo-controlled trial of nimodipine with cyclophosphamide/cisplatin for the treatment of advanced ovarian cancer

Submission date	Recruitment status	Prospectively registered
01/07/2001	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2001	Completed	Results
Last Edited	Condition category	[] Individual participant data
15/01/2019	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

G37

Study information

Scientific Title

A placebo-controlled trial of nimodipine with cyclophosphamide/cisplatin for the treatment of advanced ovarian cancer

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Ovarian cancer

Interventions

1. Arm A: Placebo tablet

2. Arm B: Nimopidine tablet

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Nimopidine

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1989

Completion date

01/01/1993

Eligibility

Key inclusion criteria

- 1. Confirmed diagnosis of invasive epithelial ovarian cancer
- 2. International Federation of Gynaecology and Obstetrics (FIGO) stages Tc Tv
- 3. 18-70 years old
- 4. Performance Status less than or equal to 2
- 5. White Blood Cells at least $4 \times 10^9/l$
- 6. Platelets at least 120 x 10^9/l
- 7. Creatinine or Ethylene Diamine Tetraacetic Acid (EDTA) clearance greater than or equal to 60 ml/min
- 8. Normal Bilirubin
- 9. Serum glutamic-oxaloacetic transaminase (SGOT)/Serum glutamic pyruvic transaminase (SGPT) less than or equal to twice normal limit
- 10. No previous chemotherapy or radiotherapy

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Upper age limit

70 Years

Sex

Female

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1989

Date of final enrolment 01/01/1993

Locations

Countries of recruitment

England

United Kingdom

Study participating centre MRC Clinical Trials Unit London United Kingdom NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

Sponsor details

PO Box 123 Lincoln's Inn Fields London United Kingdom WC2A 3PX +44 (0)207 317 5186 kate.law@cancer.org.uk

Sponsor type

Charity

Website

http://www.cancer.org.uk

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration